Eikon Therapeutics, Inc. (EIKN)

Sentiment-Signal

48,5

Neutral

Composite Score (0–100)

Insider (25%)

90.1

5 Insider, 46,1M $ Volumen

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

82.9

13D-Filing vorhanden

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Stammdaten

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of protein interactions in living cells. Its products includes EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004 are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004, to address brain metastases and primary brain malignancies; EIK1005 a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006. The company was incorporated in 2019 and is based in Millbrae, California.

Unternehmen & Branche

Name	Eikon Therapeutics, Inc.
Ticker	EIKN
CIK	0001861123
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2836 · Biological Products, (No Diagnostic Substances)

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	26,9 Mio. USD
Beta	0,00
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2026-02-06	Column Group IV GP, LP	10% Owner	Open Market Purchase	49,556	18.00	892,008.00	+13,5%
2026-02-06	Column Group IV GP, LP	10% Owner	Open Market Purchase	630,881	18.00	11,355,858.00	+172,4%
2026-02-06	Column Group IV GP, LP	10% Owner	Open Market Purchase	1,437,323	18.00	25,871,814.00	+392,7%
2026-02-04	Foresite Capital Management IV, LLC	10% Owner	Open Market Purchase	55,555	18.00	999,990.00	+15,2%
2026-02-04	Wolfe Josh	Director, 10% Owner	Open Market Purchase	138,888	18.00	2,499,984.00	+37,9%
2026-02-04	Lux Venture Partners V, LLC	10% Owner	Open Market Purchase	138,888	18.00	2,499,984.00	+37,9%
2026-02-04	FRAZIER KENNETH C	Director	Open Market Purchase	111,111	18.00	1,999,998.00	+30,4%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.